HC Wainwright Has Negative Opinion of MLYS FY2026 Earnings

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) – Research analysts at HC Wainwright cut their FY2026 earnings per share (EPS) estimates for Mineralys Therapeutics in a report released on Thursday, November 5th. HC Wainwright analyst M. Caufield now expects that the company will post earnings of ($4.56) per share for the year, down from their prior estimate of ($4.40). HC Wainwright has a “Buy” rating and a $56.00 price objective on the stock. The consensus estimate for Mineralys Therapeutics’ current full-year earnings is ($4.64) per share. HC Wainwright also issued estimates for Mineralys Therapeutics’ Q4 2026 earnings at ($0.64) EPS and FY2027 earnings at ($2.35) EPS.

Mineralys Therapeutics (NASDAQ:MLYS) last posted its earnings results on Wednesday, November 4th. The company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.09).

A number of other equities research analysts have also recently commented on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Mineralys Therapeutics in a research note on Thursday, October 15th. Zacks Research upgraded shares of Mineralys Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Friday, September 11th. UBS Group began coverage on shares of Mineralys Therapeutics in a report on Sunday, October 11th. They issued a “neutral” rating and a $29.00 price target on the stock. Finally, Wall Street Zen lowered shares of Mineralys Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 15th. Four investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $43.60.

Mineralys Therapeutics Stock Performance

NASDAQ:MLYS opened at $15.52 on Monday. Mineralys Therapeutics has a 52-week low of $14.91 and a 52-week high of $47.65. The company has a quick ratio of 11.83, a current ratio of 11.83 and a debt-to-equity ratio of 0.15. The stock has a fifty day simple moving average of $23.38 and a 200-day simple moving average of $26.44.

Insider Activity

In other Mineralys Therapeutics news, Director Brian Slingsby sold 104,320 shares of the business’s stock in a transaction on Tuesday, September 22nd. The stock was sold at an average price of $28.81, for a total value of $3,005,459.20. Following the completion of the transaction, the director directly owned 7,805,718 shares in the company, valued at approximately $224,882,735.58. The trade was a 1.32% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Daphne Karydas sold 3,000 shares of the stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $28.58, for a total value of $85,740.00. Following the transaction, the director directly owned 6,200 shares in the company, valued at approximately $177,196. This represents a 32.61% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 197,195 shares of company stock valued at $5,403,069 over the last quarter. Insiders own 18.94% of the company’s stock.

Institutional Investors Weigh In On Mineralys Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in MLYS. ProShare Advisors LLC lifted its position in Mineralys Therapeutics by 5.3% during the third quarter. ProShare Advisors LLC now owns 10,765 shares of the company’s stock worth $271,000 after buying an additional 545 shares during the period. KBC Group NV acquired a new stake in Mineralys Therapeutics in the 1st quarter worth about $33,000. Sterling Capital Management LLC boosted its stake in Mineralys Therapeutics by 902.0% in the 3rd quarter. Sterling Capital Management LLC now owns 2,024 shares of the company’s stock worth $51,000 after buying an additional 1,822 shares during the last quarter. FNY Investment Advisers LLC grew its holdings in Mineralys Therapeutics by 400.0% in the 2nd quarter. FNY Investment Advisers LLC now owns 2,500 shares of the company’s stock valued at $67,000 after buying an additional 2,000 shares during the period. Finally, Quantinno Capital Management LP grew its holdings in Mineralys Therapeutics by 12.6% in the 1st quarter. Quantinno Capital Management LP now owns 20,541 shares of the company’s stock valued at $556,000 after buying an additional 2,298 shares during the period. Hedge funds and other institutional investors own 84.46% of the company’s stock.

About Mineralys Therapeutics

Mineralys Therapeutics is a clinical-stage biopharmaceutical company developing treatments for hypertension and other cardiovascular and kidney conditions associated with excess aldosterone. The company is based in Radnor, Pennsylvania, and was founded in 2019. Its lead product candidate, lorundrostat, is an investigational oral inhibitor of aldosterone synthase. Mineralys is studying the drug as a potential treatment for difficult-to-control hypertension and conditions related to excess aldosterone; it is not an approved or marketed therapy.